Published in Vaccine Weekly, March 14th, 2001
In a recent study, T.D. Southgate and colleagues measured tissue levels of therapeutic genetic material over three months to determine both the longevity of the treatment effect and its potential safety. They found that genetic material could be observed in the pituitary three months later, though in decreasing amounts, and that pituitary hormones were not adversely affected.
After using an adenovirus vector to deliver herpes simplex...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.